Cencora (COR) Drops 5.2% After-Hours as Cardinal Health Reports Earnings

As seen on the 24/7 Wall St. homepage on November 5, 2026.

COR Cencora
After-hours
$339.52
-5.25% open $358.32
$343$341$338

A 5.25% slide to $339.53 from a $358.32 open is a sharp single-session move for a $64.8 billion distributor, and it came after Cardinal Health, a competitor, reported a Q1 FY2027 beat. Cencora has moved following 4 of 4 recent Cardinal reports.

Continue ReadingShow less

Cencora fell 5.2% in after-hours trading to $339.53, a sharp single-session move for a distributor of its size.

Cardinal Health, a direct competitor in pharmaceutical distribution, reported a Q1 FY2027 earnings beat, and Cencora has moved following each of Cardinal's last four earnings reports.

Sponsored

When one major drug distributor reports, the market tends to reprice the entire sector, since the competitive dynamics, drug pricing trends, and volume data that Cardinal reveals apply directly to Cencora's business as well.

With the after-hours price hovering near $339.53, investors will be watching whether that level holds when regular trading resumes, or whether the move deepens as more participants react to Cardinal's report.

Sources

Mentioned: COR

Related Market Updates

COR Cencora
Regular session
$343.79
-4.06% open $358.32
$363$353$343

A 4.06% slide to $343.79 from a $358.32 open lands the same session Cardinal Health, a competitor, posted a Q1 FY2027 beat, a pattern that has followed 4 of 4 Cardinal reports with a 4.0% average move.

Read more
MCK McKesson
Regular session
$1065.70
+4.57% open $1019.10
$1.1k$1k$1k

A 4.57% jump to $1,065.70 adds roughly $5 billion to this $124 billion distributor, and it comes after Cencora, a competitor, filed Q4 earnings. McKesson has followed 3 of the last 4 Cencora reports with an average 4.4% move.

Read more
Earnings · 2026 Q4 Robert P. Mauch President & CEO, Cencora
Fiscal 2026 was a pivotal year for Cencora, as we expanded our MSO platform through the acquisition of OneOncology, sharpened the focus of our portfolio and delivered record results.

Mauch is framing the $65 billion distributor as an oncology services owner, with OneOncology anchoring the MSO platform on the fiscal 2026 earnings call. The payoff investors should track is whether those practice economics keep lifting margins in fiscal 2027.

Read more
COR Cencora
Q4 2026
EPS
$4.66
est $4.57 +1.9%
Revenue
$88.35B
est $87.91B +0.5%

Cencora guided fiscal 2027 adjusted EPS to $19.40 to $19.75, implying 8% to 10% growth, after a fifth straight quarterly beat. OneOncology did the heavy lifting, and the dividend was raised to $0.66 a share.

Read more
New insider tie · Form 3 Robert E Sanchez
Now director at Cencora, Inc.

The $59 billion drug distributor just put a career logistics operator in the boardroom: Sanchez ran Ryder System as CEO before this seat went effective October 1. Supply chain execution is the whole game in pharmaceutical distribution, and the board now reflects that.

Read more